Drug Dosing in Kidney Disease

Meet the patient

Kidney disease changes drug exposure through reduced renal clearance, altered tubular transport, fluid expansion, hypoalbuminaemia and uraemic changes in protein binding. Renal replacement therapy can add variable extracorporeal clearance. The clinical aim is not simply to “reduce the dose”; it is to reach the exposure required for the indication without avoidable toxicity.^[1]

The phrase renal dose is incomplete unless it specifies five things: the patient, the indication and severity, the current product label or local monograph, the kidney-function metric and trajectory, and the dialysis prescription if present.^[1][2]

Classification: five prescribing questions

Enlarge

The useful bedside categories are:^[1][6][9]

1. Exposure likely to rise because parent drug or active metabolite is renally cleared.
2. Kidney harm or haemodynamic stress may occur in a susceptible context.
3. Measured exposure can guide therapy through appropriately timed therapeutic drug monitoring.
4. The label uses a renal threshold that must be read with its indication and jurisdiction.
5. Dialysis may remove the drug, but only after the modality and session are defined.^[1][6][9]

Estimating kidney function for a prescription

Stable kidney function

For a stable creatinine, start with a validated race-free eGFR equation. The 2021 CKD-EPI creatinine and creatinine-cystatin C equations are the modern race-free equations; the older 2009 CKD-EPI paper is not a source for the 2021 equation.^[3]

Use combined creatinine-cystatin C eGFR when creatinine is likely misleading or when greater accuracy changes a high-consequence decision. Consider measured GFR or measured clearance for a narrow-therapeutic-index drug when estimates remain discordant.^[2][3]

If body surface area differs substantially from 1.73 m² and the dosing source expects absolute mL/min, a clinician may de-index: absolute GFR = indexed eGFR × BSA / 1.73. Do not de-index automatically when the label itself specifies indexed eGFR.^[2]

Cockcroft-Gault remains important when the specific label or evidence base requires it, but its weight term is a source of error at extremes of body size. There is no universal “use adjusted weight above one fixed percentage” rule; follow the source and seek pharmacy support when the dose band changes with the weight assumption.^[4]

Non-steady-state AKI

A kinetic GFR estimate can describe changing filtration and may help an expert discussion, but it is not a universally validated substitute for drug-specific dosing evidence. It must not delay treatment or replace repeated bedside reassessment.^[5]

When creatinine is unreliable

• Low muscle mass, amputation, frailty or cirrhosis: creatinine may overestimate filtration; cystatin C also has non-GFR determinants, so use combined eGFR or measured GFR when the decision is critical.^[2][3]
• Extreme body size: distinguish indexed mL/min/1.73 m² from absolute mL/min and follow the label's units.^[2]
• Pregnancy: routine creatinine- and cystatin-based eGFR equations are not validated for drug dosing in pregnancy. Use serial serum creatinine and the clinical trajectory; if a high-consequence dose requires a clearance estimate, seek obstetric-nephrology/pharmacy input and use a pregnancy-appropriate measured method rather than silently applying a standard eGFR equation.^[14]

Pathophysiology & pharmacokinetics

Enlarge

Clearance, binding and distribution

Glomerular filtration mainly clears unbound drug; molecular size, shape, charge and protein binding all matter. Active tubular secretion and reabsorption add drug-specific transport and interaction effects.^[1]

Hypoalbuminaemia and uraemia can increase the unbound fraction of highly protein-bound drugs, so a total concentration may not reliably represent active exposure. Interpret any level using a drug-specific source, the sampling time, clinical effect and toxicity rather than applying an unsourced generic correction.^[1]

Fluid resuscitation, oedema, sepsis and critical illness can expand the volume of distribution of hydrophilic drugs. Therefore the loading dose is not automatically unchanged or reduced: loading exposure follows target concentration and volume of distribution, whereas maintenance exposure follows clearance and the PK/PD target.^[1][6]

Time-dependent beta-lactams may need preservation of dosing frequency or prolonged infusion to maintain time above the MIC, while concentration-dependent aminoglycoside regimens may preserve a dose and alter the interval. Exact regimens and concentration targets are agent-, indication-, population- and protocol-specific.^[6]

Kidney injury is not one mechanism

NSAIDs can impair prostaglandin-dependent afferent vasodilatation, especially with hypovolaemia, heart failure or cirrhosis. ACE inhibitors and ARBs reduce efferent tone and are disease-modifying therapies, not simple “direct nephrotoxins”; an expected creatinine change and potassium require clinical assessment, not automatic permanent discontinuation.^[1][2]

Use contrast-associated AKI when causality is not established. Modern controlled evidence suggests the risk from intravenous iodinated contrast was historically overstated; balance diagnostic benefit, baseline AKI or severe CKD, route and volume status, and use prophylactic isotonic saline where indicated. Necessary imaging should not be reflexively denied.^[10]

The safe prescribing loop

Enlarge

^{[1] [2]}

High-yield source-specific examples

Vancomycin

For serious MRSA infection, the 2020 consensus guideline replaces trough-only monitoring with an AUC24/MIC target of 400 to 600 mg·h/L, calculated with a broth-microdilution MIC of 1 mg/L. Trough-guided dosing, including the old 15 to 20 mg/L target, is associated with higher nephrotoxicity than AUC-guided dosing. Loading and maintenance doses are chosen for the individual patient from illness severity, body size, kidney function and dialysis requirement.^[7]

Vancomycin plus piperacillin-tazobactam

The combination is associated in observational studies with more creatinine-defined AKI than some comparators, but “synergistic nephrotoxicity” is too certain. A prospective biomarker study found an early creatinine signal without parallel cystatin C, BUN, dialysis or mortality signals, supporting possible inhibition of creatinine secretion or pseudo-AKI in at least some cases. Choose antibiotics from source, cultures, resistance, allergy, toxicity and PK/PD—not an automatic cefepime substitution.^[8]

Metformin

Metformin is renally cleared, and accumulation raises the risk of lactic acidosis. A systematic review found that drug levels stay in the therapeutic range and lactate concentrations do not rise substantially at an eGFR of 30 to 60 mL/min/1.73 m², and supports continued use in mild to moderate CKD with dose reduction and follow-up of kidney function.^[21] Current practice guidance is to review the dose when eGFR is 30 to 60 mL/min/1.73 m² and stop metformin below 30 mL/min/1.73 m². Concomitant hypolactataemic risk factors—liver or respiratory insufficiency, sepsis, acute heart failure—contraindicate metformin regardless of eGFR.^[17]

Apixaban: why indication matters

Apixaban is a direct factor Xa inhibitor with about 50% oral bioavailability; around 27% of its clearance is renal, and fixed dosing without therapeutic drug monitoring is standard across most patient groups.^[22] For stroke prevention in nonvalvular atrial fibrillation, the label reduces the dose when at least two of three are present: age 80 years or over, body weight 60 kg or less, and serum creatinine 1.5 mg/dL or more. In one registry of patients starting apixaban for atrial fibrillation, nearly half received the reduced dose and most of those did not meet any reduction criterion—age, weight and creatinine each predicted underdosing.^[18] Dose criteria differ by indication and jurisdiction; check the current local product label.

Nitrofurantoin: why jurisdiction matters

Nitrofurantoin needs concentration in urine to work, so impaired renal excretion threatens both efficacy and toxicity. The contraindication at a creatinine clearance below 60 mL/min entered US product information between 1988 and 2003; a review found no trial evidence behind that threshold and concluded that the limited data support use down to a creatinine clearance of 40 mL/min.^[19] Jurisdictions now disagree: some regulators restrict nitrofurantoin below an eGFR of 45 mL/min/1.73 m² while others allow it at 30 or above. Read the current local product label before prescribing.

Allopurinol: do not cap maintenance by eGFR alone

For gout, start allopurinol low—no more than 100 mg/day, and lower in CKD—then titrate to a serum urate target below 6 mg/dL.^[13] Dose escalation above the creatinine-clearance-based ceiling reached that target in most patients, including those with renal impairment, without excess toxicity.^[23] In severe CKD the doses needed were lower—about 250 mg/day on average below a creatinine clearance of 30 mL/min—but urate fell to target as often as in better kidney function, and adverse events were similar.^[24] HLA-B*58:01 screening before starting allopurinol, with an alternative drug for carriers, cut the incidence of severe cutaneous adverse reactions to zero in a Taiwanese national cohort where 19.6% carried the allele; test selected higher-risk ancestry groups where regional guidance recommends it.^[20]

Dialysis and kidney replacement therapy

Do not prescribe “a post-dialysis top-up” from a generic list. Removal depends on molecular size, protein binding, volume of distribution, treatment prescription, dose timing and residual kidney function. Name the modality—intermittent haemodialysis, CAPD, APD, prolonged intermittent therapy or CRRT—and use a current indication-specific source.^[1][9][15]

For CRRT, record modality, effluent rate, residual kidney function, interruptions and filter changes. “CRRT equals a GFR of 20 to 40” is not a safe universal conversion. Use a current modality-specific institutional reference and TDM when available.^[9]

Peritoneal dialysis is not one interchangeable prescription. Distinguish continuous ambulatory peritoneal dialysis (CAPD) from automated peritoneal dialysis (APD); record residual kidney function, exchange volume, exchange frequency or cycler schedule, cycle and dwell duration including any long dwell, route of administration and dose timing. Clearance and exposure are drug- and prescription-specific, and PD evidence is limited. Do not transfer a CAPD long-dwell regimen directly to APD or infer a generic post-dialysis replacement dose; use a current indication-specific PD source and TDM where available.^[15][16]

Monitoring and interpretation

• Measure clinical effect: infection response, bleeding or thrombosis, seizure control, pain or urate target—not only serum creatinine.^[1]
• Time levels correctly: sampling depends on the drug, indication and regimen; a random level is not automatically a trough.^[1][6]
• Trend toxicity: mental status, respiratory rate, ECG, potassium, magnesium, glucose, blood count and liver tests as the drug requires.^[1]

Temporary holds and sick-day advice

Sick-day rules are not a universal mnemonic with a guaranteed 24- to 48-hour restart. Evidence for preventing AKI during community intercurrent illness is limited, and failure to restart beneficial medicines can cause harm.^[11][12]

Give an individual written plan that states:^[2][11][12]

1. the trigger—such as vomiting, diarrhoea, poor intake, hypotension or suspected AKI;
2. which named medicines to pause and why;
3. which medicines must continue or need urgent specialist advice;
4. when to seek clinical review and what to monitor; and
5. the explicit restart condition, responsible clinician and follow-up test.^[2][11][12]

For any proposed temporary hold, name the medicine and current indication, define the immediate toxicity or physiological risk, decide whether an alternative or urgent specialist plan is needed, specify monitoring, and document the review and restart condition. Do not convert this individualized balance into a class-wide stop or continue rule without a class-specific source.^[2][11][12]

Bedside assessment and investigations

At every admission, transition and major physiological change:^[1][2]

• reconcile prescription, over-the-counter and herbal medicines;
• record the exact indication, dose, route and last administration time;
• assess blood pressure, perfusion, fluid balance, body weight and urine output;
• plot creatinine and electrolytes rather than reading one value;
• identify interacting drugs and altered protein binding;
• document dialysis modality and schedule;
• ask pharmacy or nephrology when estimates disagree or the therapeutic window is narrow.^[1][2]

Exam application

Stable CKD stem

State the drug and indication; identify the kidney metric used in the current label; check whether indexed or absolute units are expected; review body size, interactions and dialysis; prescribe the label- or monograph-based regimen; and plan monitoring.^[2][4]

Evolving AKI stem

Say “non-steady state”: use creatinine trajectory, urine output, haemodynamics, prior exposure, levels and response. Protect time-critical treatment by separating loading from maintenance, then reassess after each dose or physiological change.^[1][5][6]

Dialysis stem

Name intermittent HD, CAPD or APD, prolonged intermittent therapy or CRRT; state residual kidney function and the actual treatment settings. For PD, include exchange volume, cycle/dwell schedule, route and timing. Determine dialysability and use a current modality- and indication-specific source or TDM; never transfer a CAPD long-dwell regimen directly to APD.^{[1][9][15][16]}

References24ShowHide

1. [1]Lea-Henry TN, Carland JE, Stocker SL, et al. Clinical Pharmacokinetics in Kidney Disease: Fundamental Principles Clin J Am Soc Nephrol, 2018.PMID 29934432
2. [2]Levin A, Ahmed SB, Carrero JJ, et al. Executive summary of the KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease: known knowns and known unknowns Kidney Int, 2024.PMID 38519239
3. [3]Inker LA, Eneanya ND, Coresh J, et al. New Creatinine- and Cystatin C-Based Equations to Estimate GFR without Race N Engl J Med, 2021.PMID 34554658
4. [4]Wilhelm SM, Kale-Pradhan PB. Estimating creatinine clearance: a meta-analysis Pharmacotherapy, 2011.PMID 21923452
5. [5]Chen S. Retooling the creatinine clearance equation to estimate kinetic GFR when the plasma creatinine is changing acutely J Am Soc Nephrol, 2013.PMID 23704286
6. [6]Eyler RF, Shvets K. Clinical Pharmacology of Antibiotics Clin J Am Soc Nephrol, 2019.PMID 30862698
7. [7]Rybak MJ, Le J, Lodise TP, et al. Therapeutic Monitoring of Vancomycin for Serious Methicillin-resistant Staphylococcus aureus Infections: A Revised Consensus Guideline and Review by the American Society of Health-system Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists Clin Infect Dis, 2020.PMID 32658968
8. [8]Miano TA, Hennessy S, Yang W, et al. Association of vancomycin plus piperacillin-tazobactam with early changes in creatinine versus cystatin C in critically ill adults: a prospective cohort study Intensive Care Med, 2022.PMID 35833959
9. [9]Hoff BM, Maker JH, Dager WE, Heintz BH. Antibiotic Dosing for Critically Ill Adult Patients Receiving Intermittent Hemodialysis, Prolonged Intermittent Renal Replacement Therapy, and Continuous Renal Replacement Therapy: An Update Ann Pharmacother, 2020.PMID 31342772
10. [10]Davenport MS, Perazella MA, Yee J, et al. Use of Intravenous Iodinated Contrast Media in Patients with Kidney Disease: Consensus Statements from the American College of Radiology and the National Kidney Foundation Radiology, 2020.PMID 31961246
11. [11]Watson KE, Dhaliwal K, McMurtry E, et al. Sick Day Medication Guidance for People With Diabetes, Kidney Disease, or Cardiovascular Disease: A Systematic Scoping Review Kidney Med, 2022.PMID 36046611
12. [12]Whiting P, Morden A, Tomlinson LA, et al. What are the risks and benefits of temporarily discontinuing medications to prevent acute kidney injury? A systematic review and meta-analysis BMJ Open, 2017.PMID 28389482
13. [13]FitzGerald JD, Dalbeth N, Mikuls T, et al. 2020 American College of Rheumatology Guideline for the Management of Gout Arthritis Care Res (Hoboken), 2020.PMID 32391934
14. [14]Hart LA, Anderson GD. Methods of Estimating Kidney Function for Drug Dosing in Special Populations Clin Pharmacokinet, 2018.PMID 29357102
15. [15]Vilay AM. Antibiotic Dosing in Chronic Kidney Disease and End-Stage Renal Disease: A Focus on Contemporary Challenges Adv Chronic Kidney Dis, 2019.PMID 30876619
16. [16]Mancini A, Piraino B. Review of Antibiotic Dosing with Peritonitis in APD Perit Dial Int, 2019.PMID 31296775
17. [17]Silverii GA Optimizing metformin therapy in practice: Tailoring therapy in specific patient groups to improve tolerability, efficacy and outcomes Diabetes Obes Metab, 2024.PMID 38987983
18. [18]Buchholz A, Ueberham L, Gorczynska K, et al. Initial apixaban dosing in patients with atrial fibrillation Clin Cardiol, 2018.PMID 29542830
19. [19]Oplinger M, Andrews P. Nitrofurantoin contraindication in patients with a creatinine clearance below 60 mL/min: looking for the evidence Ann Pharmacother, 2013.PMID 23341159
20. [20]Ko TM, Tsai CY, Chen SY, et al. Use of HLA-B*58:01 genotyping to prevent allopurinol induced severe cutaneous adverse reactions in Taiwan: national prospective cohort study BMJ, 2015.PMID 26399967
21. [21]Inzucchi SE, Lipska KJ, Mayo H, et al. Metformin in patients with type 2 diabetes and kidney disease: a systematic review JAMA, 2014.PMID 25536258
22. [22]Byon W, Garonzik S, Boyd RA, Frost GI. Apixaban: A Clinical Pharmacokinetic and Pharmacodynamic Review Clin Pharmacokinet, 2019.PMID 31089975
23. [23]Stamp LK, O'Donnell JL, Zhang M, et al. Using allopurinol above the dose based on creatinine clearance is effective and safe in patients with chronic gout, including those with renal impairment Arthritis Rheum, 2011.PMID 21279998
24. [24]Stamp LK, Chapman PT, Barclay M, et al. The effect of kidney function on the urate lowering effect and safety of increasing allopurinol above doses based on creatinine clearance: a post hoc analysis of a randomized controlled trial Arthritis Res Ther, 2017.PMID 29268756